ReviewMechanisms of Drug Toxicity and Relevance to Pharmaceutical Development
References (81)
- et al.
Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone
Toxicol. Appl. Pharmacol.
(2004) - et al.
Animal models of idiosyncratic drug reactions
Chem. Biol. Interact.
(2004) - et al.
Autoantibodies against cytochromes P450: role in human diseases
Adv. Pharmacol.
(1994) - et al.
Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor
Chem. Biol. Interact.
(2004) - et al.
Cellular mechanisms of T cell mediated drug hypersensitivity
Curr. Opin. Immunol.
(2004) - et al.
Hydralazine and other hydrazine derivatives and the formation of DNA adducts
Toxicol. Appl. Pharmacol.
(1994) - et al.
Metabolic activation of the tricyclic antidepressant amineptine. I. Cytochrome P-450-mediated in vitro covalent binding
Biochem. Pharmacol.
(1987) - et al.
In vitro metabolism of isaxonine phosphate: formation of two metabolites, 5-hydroxyisaxonine and 2-aminopyrimidine, and covalent binding to microsomal proteins
Eur. J. Pharmacol.
(1992) - et al.
N-Deacetyl ketoconazoleinduced hepatotoxicity in a primary culture system of rat hepatocytes
Toxicology
(1997) - et al.
Acetaminophen structure-toxicity studies: in vivo covalent binding of a nonhepatotoxic analog, 3-hydroxyacetanilide
Toxicol. Appl. Pharmacol.
(1990)
Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a non-hepatotoxic regioisomer, 3′-hydroxyacetanilide, in mouse liver
J. Biol. Chem.
(1989)
Mitochondria-targeted cytochrome P450 2E1 preferentially induces oxidative damage and augments alcohol mediated mitochondrial dysfunction in cultured cells
J. Biol. Chem.
(2010)
Mitochondrial abnormalities¯a link to idiosyncratic drug hepatotoxicity?
Toxicol. Appl. Pharmacol.
(2007)
Troglitazone-induced hepatic mitochondrial proteome expression dynamics in heterozygous Sod2 +/– mice: Two-stage oxidative injury
Toxicol. Appl. Pharmacol.
(2008)
Strategic applications of toxicogenomics in early drug discovery
Curr. Opin. Pharmacol.
(2008)
The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity
Toxicol. Appl. Pharmacol.
(2010)
U.S. Food and Drug Administration: Challenge and opportunity on the critical path to new medical products
(March 2004)
Can the pharmaceutical industry reduce attrition rates?
Nat. Rev. Drug Discov.
(2004)
Paracelsus: herald of modern toxicology
Toxicol. Sci.
(2000)
Elucidating mechanisms of drug-induced toxicity
Nat. Rev. Drug Discov.
(2005)
The role of metabolic activation in druginduced hepatotoxicity
Annu. Rev. Pharmacol. Toxicol.
(2005)
Rosuvastatin: an independent analysis of risks and benefits
MedGenMed
(2006)
Studies on the sensitization of animals with simple chemical compounds
J. Exp. Med.
(1935)
Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals in the Liver
(1999)
Drug-induced liver injury: Hy's rule revisited
Clin. Pharmacol. Ther.
(2006)
Idiosyncratic drug reactions: current understanding
Annu. Rev. Pharmacol. Toxicol.
(2007)
Idiosyncratic drug reactions: past, present, and future
Chem. Res. Toxicol.
(2008)
Immune-mediated adverse drug reactions
Chem. Res. Toxicol.
(2009)
Mechanisms of immune-mediated liver injury
Toxicol. Sci.
(2010)
New concepts in immunology relevant to idiosyncratic drug reactions: the “danger hypothesis” and innate immune system
Chem. Res. Toxicol.
(1999)
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
Proc. Natl. Acad. Sci. U.S.A.
(1993)
A new anti-liver endoplasmic reticulum antibody directed against human cytochrome P-450 IA2: a specific marker of dihydralazine-induced hepatitis
J. Clin. Invest.
(1990)
Drug-induced immunotoxicity
Eur. J. Drug Metab. Pharmacokinet.
(1998)
Bacterial lipopolysaccharide exposure alters aflatoxin B1 hepatotoxicity: benchmark dose analysis for markers of liver injury
Toxicol. Sci.
(2002)
The danger model: a renewed sense of self
Science
(2002)
Friendly and dangerous signals: is the tissue in control?
Nat. Immunol.
(2007)
Delayed drug hypersensitivity reactions
Ann. Intern. Med.
(2003)
Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis
Pharmacogenet. J.
(2008)
Applying mechanisms of chemical toxicity to predict drug safety
Chem. Res. Toxicol.
(2007)
Acetaminophen-induced hepatic necrosis
II. Role of covalent binding in vivo. J. Pharmacol. Exp. Ther.
(1973)
Cited by (0)
Copyright © 2011 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.